Biodegradable drug delivery compositions

Abstract

A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as a pharmaceutically active principle is disclosed.

1 . (canceled) 
     
     
         2 . A biodegradable drug delivery composition comprising:
 (a) a biodegradable triblock copolymer present in an amount of 3.0% to 45% (w %/w %) of the total composition having the formula:   Poly(lactic acid)v-poly(ethylene glycol)w-poly(lactic acid)x   wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 and v=x or v≠x;   (b) a biodegradable diblock copolymer present in an amount of 8.0% to 50% (w %/w %) of the total composition having the formula:   methoxy poly(ethylene glycol)y-poly(lactic acid)z   wherein y and z are the number of repeat units y ranging from 3 to 45 and z ranging from 7 to 327, wherein the ratio of the biodegradable triblock copolymer of (a) and the biodegradable di block copolymer of (b) is 1:3 to 1:8 or 1:1 to 1:19 or 3:2 to 1:19 in said biodegradable drug composition; and   (c) an organic solvent present in an amount of 40%-74% (w %/w %) of the total composition; and   (d) at least one pharmaceutically active principle.   
     
     
         3 . The biodegradable drug delivery composition of  claim 2 , wherein
 the biodegradable triblock copolymer is present in an amount of 6% to 10% (w %/w %) of the total composition;   the biodegradable diblock copolymer is present in an amount of 10% to 20% (w %/w %) of the total composition; and   the organic solvent is present in an amount of 40% (w %/w %) of the total composition.   
     
     
         4 . A biodegradable drug delivery composition consisting of
 (a) a biodegradable triblock copolymer present in an amount of 6% to 10% (w %/w %) of the total composition having the formula:   Poly(lactic acid)v-poly(ethylene glycol)w-poly(lactic acid)x   wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 and v=x or v≠x;   (b) a biodegradable diblock copolymer present in an amount of 10% to 20% (w %/w %) of the total composition having the formula:   methoxy poly(ethylene glycol)y-poly(lactic acid)z   wherein y and z are the number of repeat units y ranging from 3 to 45 and z ranging from 7 to 327, wherein the ratio of the biodegradable triblock copolymer of (a) and the biodegradable di block copolymer of (b) is 1:3 to 1:8 or 1:1 to 1:19 or 3:2 to 1:19 in said biodegradable drug composition; and   (c) an organic solvent present in an amount of 40% (w %/w %) of the total composition; and   (d) at least one pharmaceutically active principle.   
     
     
         5 . The biodegradable drug delivery composition of  claim 3 , wherein the pharmaceutically active principle is M53, acetaminophen, buprenorphine, risperidone, or ivermectin. 
     
     
         6 . The biodegradable drug delivery composition of  claim 4 , wherein the pharmaceutically active principle is M53, acetaminophen, buprenorphine, risperidone, or ivermectin. 
     
     
         7 . The biodegradable drug delivery composition of  claim 3 , wherein the organic solvent is diethylene glycol dimethyl ether (Diglyme), diethylene glycol monoethyl ether (DEGMEE), dimethyl sulfoxide (DMSO), or ethyl lactate. 
     
     
         8 . The biodegradable drug delivery composition of  claim 4 , wherein the organic solvent is diethylene glycol dimethyl ether (Diglyme), diethylene glycol monoethyl ether (DEGMEE), dimethyl sulfoxide (DMSO), or ethyl lactate. 
     
     
         9 . The biodegradable drug delivery composition of  claim 7 , wherein the organic solvent is dimethyl sulfoxide (DMSO). 
     
     
         10 . The biodegradable drug delivery composition of  claim 8 , wherein the organic solvent is dimethyl sulfoxide (DMSO).